ABSTRACT
Background: This study aims to evaluate waning effectiveness against severe and fatal COVID-19 with two to three doses of CoronaVac/BNT162b2, where data are limited. Methods: A case–control study included individuals aged ≥18 years, unvaccinated or received two to three doses of CoronaVac/BNT162b2, using electronic healthcare databases in Hong Kong. Those with first COVID-19-related hospitalization, severe complications, or mortality between 1 January and 15 August 2022 were defined as cases and matched with up-to-10 controls by age, sex, index date, and Charlson Comorbidity Index. Vaccine effectiveness (VE) against COVID-19-related outcomes was estimated at different time intervals from second and third-dose vaccination (0–13 up-to 210–240 days) using conditional logistic regression adjusted for comorbidities and medications. Results: By 211–240 days after second dose, VE against COVID-19-related hospitalization reduced to 46.6% (40.7–51.8%) for BNT162b2 and 36.2% (28.0–43.4%) for CoronaVac, and VE against COVID-19-related mortality were 73.8% (55.9–84.4%) and 76.6% (60.8–86.0%). After third dose, VE against COVID-19-related hospitalization decreased from 91.2% (89.5–92.6%) for BNT162b2 and 76.7% (73.7–79.4%) for CoronaVac at 0–13 days, to 67.1% (60.4–72.6%) and 51.3% (44.2–57.5%) at 91–120 days. VE against COVID-19-related mortality for BNT162b2 remained high from 0–13 days [98.2% (95.0–99.3%)] to 91–120 days [94.6% (77.7–98.7%)], and for CoronaVac reduced from 0–13 days [96.7% (93.2–98.4%)] to 91–120 days [86.4% (73.3–93.1%)]. Conclusions: Significant risk reduction against COVID-19-related hospitalization and mortality after CoronaVac or BNT162b2 vaccination was observed for >240 and >120 days after second and third doses compared to unvaccinated, despite significant waning over time. Timely administration of booster doses could provide higher levels of protection.
Acknowledgements
We gratefully acknowledge the Centre for Health Protection, Department of Health and Hospital Authority for facilitating data access. ICKW is partially supported by the Laboratory of Data Discovery for Health (D24H) funded by AIR@InnoHK administered by the Innovation and Technology Commission. The corresponding authors had full access to all the data in the study and took final responsibility for the decision to submit for publication. Concept and design were prepared by VKCY, EYFW, ICKW, EWC. Acquisition, analysis, or interpretation of data was formulated by VKCY, EYFW, XY, FTTL, CSLC, XL, CKHW, PHL, TM, SQ, ICKW, EWC. Drafting of the manuscript was bone by VKCY, EYFW, AHYM. Critical revision of the manuscript for important intellectual content was done by all the authors. Statistical analysis: VKCY, EYFW, XY. Administrative, technical, or material support was given by ICKW, EWC. ICKW, EWC supervised the whole process.
Disclosure statement
No potential conflict of interest was reported by the author(s).
Data sharing
Data are not available as the data custodians (the Hospital Authority and the Department of Health of Hong Kong SAR) have not given permission for sharing due to patient confidentiality and privacy concerns. Local academic institutions, government departments, or non-governmental organizations may apply for the access to data through the Hospital Authority’s data sharing portal (https://www3.ha.org.hk/data).